Our team, led by Dr. Marcel Kool, is part of the Division of Pediatric Neurooncology at the DKFZ and the division of the same name at the KiTZ. We investigate the genetic and epigenetic causes of various rare and often aggressive brain tumors, including medulloblastomas, ependymomas, ATRTs, ETMRs and CNS PNETs. We are particularly interested in newly discovered molecular subgroups such as CNS-NB-FOXR2 activated, CNS-EFT-CIC, HGNET-BCOR and HGNET-MN1.
For our investigations we use state-of-the-art technologies such as high-throughput DNA and (mi)RNA sequencing, DNA methylation analysis, RNA profiling and ChIP sequencing.
In recent years, we have been able to decipher many of the mechanisms that drive these tumors. However, there are still unanswered questions, particularly regarding possible triggers and new therapeutic approaches. That is why we are also using innovative methods such as single-cell omics to analyze tumors even more specifically and develop better treatment options.
Our research goal
Our goal is to better understand rare brain tumors and to identify their molecular subgroups as well as the underlying genetic drivers and signaling pathways. Of particular importance is the development of suitable human and animal model systems that realistically represent the disease and take into account the complex tumor heterogeneity. We are also specifically looking for new therapeutic approaches in order to develop effective treatment strategies.
The findings from our genetic analyses should flow directly into new treatment strategies in order to improve the therapy of affected patients.
Development of new therapeutic approaches
We conduct targeted research into new drug targets - often in combination with established chemotherapeutics or cytostatics. To this end, we use various model systems, including cell lines, patient-derived orthotopic xenografts (PDX) and organoid cultures.
We are currently concentrating on the targeted therapy of certain brain tumors, including
- MYC(N)-driven tumors,
- SHH-driven medulloblastomas,
- PFA and RELA ependymomas,
- ETMR tumors.
We are testing a broad spectrum of drugs in order to develop new, more effective treatment options.
